Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021

3 years ago

NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company…

Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer

3 years ago

-- Single-cell proteomics can elucidate kinase activity in prostate cancer models -- -- Kinase activity in bone metastases and epithelial…

Rapid Micro Biosystems Appoints Michael Beaulieu as Vice President, Investor Relations and Corporate Communications

3 years ago

LOWELL, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences…

Conformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022

3 years ago

BILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that as mentioned on its Business…

Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer

3 years ago

Session will include a discussion of the treatment landscape for Mantle Cell Lymphoma, including potential role of Zilovertamab, Oncternal’s ROR1…

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

3 years ago

The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as…

Intuitive Announces Fourth Quarter Earnings

3 years ago

SUNNYVALE, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive…

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

3 years ago

Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement…

Maravai LifeSciences Announces Debt Repricing

3 years ago

Lowers Interest Rates on Current Debt to Provide Approximately $6.8 Million in Annual Interest SavingsSAN DIEGO, Jan. 20, 2022 (GLOBE…

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

3 years ago

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume…